Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Forest Labs (FRX - Analyst Report) and Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, recently signed a collaboration agreement. The companies will work on the development of novel mPGES-1 inhibitors for the treatment of chronic inflammatory conditions, including pain.

Potential candidates have already been identified by Glenmark. Glenmark is conducting pre-clinical studies with these candidates prior to the initiation of human studies.

Glenmark will receive an upfront payment of $6 million from Forest Labs. Moreover, Forest Labs will pay $3 million to fund the next phase of work. Additional payments will be made by Forest Labs in fiscal 2014 to support the development program. Once phase I development is completed, Forest Labs has an exclusive option to acquire licensing rights to the program.

With this deal, Glenmark is gaining a strong commercialization partner like Forest Labs. Meanwhile, the deal is in line with Forest Labs’ efforts to expand its pipeline. Forest Labs is facing tough times with Lexapro losing patent protection. Over the past few years, Forest Labs has been very active in signing in-licensing and partnership deals with the intention of expanding its pipeline. The company has licensing agreements with several companies like Almirall SA, AstraZeneca (AZN - Analyst Report), and Ironwood Pharma (IRWD - Analyst Report) among others.

We currently have a Neutral recommendation on Forest Labs, which carries a Zacks #3 Rank (Hold). Following the release of second quarter results, Forest Labs once again cut its outlook for fiscal 2013. More than Lexapro’s genericization, the cut in Namenda’s guidance is disappointing as Namenda is currently the main contributor to the company’s top line. Moreover, the performance of new products especially Teflaro, has been below expectations. We note that Namenda will face generic competition in early 2015 putting another $1+ billion at risk.

Both Ironwood Pharma and AstraZeneca are Zacks #2 Rank (Buy) stocks.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%